Originally published as JCO Early Release 10.1200/JCO.2005.10.080 on March 28 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herrinton, L. J. Articles by Fletcher, S. W. Search for Related Content PubMed PubMed Citation Articles by Herrinton, L. J. Articles by Fletcher, S. W. Related Articles Related Editorial

Efficacy of Prophylactic Mastectomy in Women With Unilateral Breast Cancer: A Cancer Research Network Project

From the Cancer Research Network, Kaiser Permanente Northern California, Oakland; Kaiser Permanente Southern California, Pasadena, CA; Group Health Cooperative; University of Washington Department of Biostatistics and School of Medicine, Seattle, WA; Harvard Pilgrim Health Care and Harvard Medical School, Boston, MA; Kaiser Permanente Northwest Center for Health Research, Portland, OR; and HealthPartners, Minneapolis, MN

Address reprint requests to Lisa J. Herrinton, PhD, Division of Research, Northern California Kaiser Permanente, 2000 Broadway Ave, Oakland, CA 94612; e-mail: lisa.herrinton{at}kp.org

PURPOSE: We investigated the efficacy of contralateral prophylactic mastectomy (CPM) in reducing contralateral breast cancer incidence and breast cancer mortality among women who have already been diagnosed with breast cancer.

METHODS: This retrospective cohort study comprised approximately 50,000 women who were diagnosed with unilateral breast cancer during 1979 to 1999. Using computerized data confirmed by chart review, we identified 1,072 women (1.9%) who had CPM. We obtained covariate information for these women and for a sample of 317 women who did not undergo CPM.

RESULTS: The median time from initial breast cancer diagnosis to the end of follow-up was 5.7 years. Contralateral breast cancer developed in 0.5% of women with CPM, metastatic disease developed in 10.5%, and subsequent breast cancer developed in 12.4%; 8.1% died from breast cancer. Contralateral breast cancer developed in 2.7% of women without CPM, and 11.7% died of breast cancer. After adjustment for initial breast cancer characteristics, treatment, and breast cancer risk factors, the hazard ratio (HR) for the occurrence of contralateral breast cancer after CPM was 0.03 (95% CI, 0.006 to 0.13). After adjustment for breast cancer characteristics and treatment, the HRs for the relationship of CPM with death from breast cancer, with death from other causes, and with all-cause mortality were 0.57 (95% CI, 0.45 to 0.72), 0.78 (95% CI, 0.57 to 1.06), and 0.60 (95% CI, 0.50 to 0.72), respectively.

CONCLUSION: CPM seems to protect against the development of contralateral breast cancer, and although women who underwent CPM had relatively low all-cause mortality, CPM also was associated with decreased breast cancer mortality.

Supported by grant No. U19 CA NCI 79689 from the National Cancer Institute, Bethesda, MD.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Related Editorial

• Contralateral Prophylactic Mastectomy: Quantifying Benefits and Weighing the Harms
  Kathy J. Helzlsouer
  JCO 2005 23: 4251-4253 [Full Text]

This article has been cited by other articles:

				P. Mor and K. Oberle Ethical Issues Related To BRCA Gene Testing in Orthodox Jewish Women Nursing Ethics, July 1, 2008; 15(4): 512 - 522. [Abstract] [PDF]

				S. van Dijk, M. S. van Roosmalen, W. Otten, and P. F.M. Stalmeier Decision Making Regarding Prophylactic Mastectomy: Stability of Preferences and the Impact of Anticipated Feelings of Regret J. Clin. Oncol., May 10, 2008; 26(14): 2358 - 2363. [Abstract] [Full Text] [PDF]

				E. Briasoulis and D. H. Roukos Contralateral Prophylactic Mastectomy: Mind the Genetics J. Clin. Oncol., April 10, 2008; 26(11): 1909 - 1910. [Full Text] [PDF]

				T. M. Tuttle, E. B. Habermann, and B. A. Virnig In Reply J. Clin. Oncol., April 10, 2008; 26(11): 1910 - 1910. [Full Text] [PDF]

				K. A. Metcalfe, J. Lubinski, P. Ghadirian, H. Lynch, C. Kim-Sing, E. Friedman, W. D. Foulkes, S. Domchek, P. Ainsworth, C. Isaacs, et al. Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group J. Clin. Oncol., March 1, 2008; 26(7): 1093 - 1097. [Abstract] [Full Text] [PDF]

				D. J. Brenner, I. Shuryak, S. Russo, and R. K. Sachs In Reply: J. Clin. Oncol., February 20, 2008; 26(6): 1015 - 1016. [Full Text] [PDF]

				T. M. Tuttle, E. B. Habermann, E. H. Grund, T. J. Morris, and B. A. Virnig Increasing Use of Contralateral Prophylactic Mastectomy for Breast Cancer Patients: A Trend Toward More Aggressive Surgical Treatment J. Clin. Oncol., November 20, 2007; 25(33): 5203 - 5209. [Abstract] [Full Text] [PDF]

				J. N. Weitzel, V. I. Lagos, C. A. Cullinane, P. J. Gambol, J. O. Culver, K. R. Blazer, M. R. Palomares, K. J. Lowstuter, and D. J. MacDonald Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer JAMA, June 20, 2007; 297(23): 2587 - 2595. [Abstract] [Full Text] [PDF]

				C. D. Lehman, C. Gatsonis, C. K. Kuhl, R. E. Hendrick, E. D. Pisano, L. Hanna, S. Peacock, S. F. Smazal, D. D. Maki, T. B. Julian, et al. MRI Evaluation of the Contralateral Breast in Women with Recently Diagnosed Breast Cancer N. Engl. J. Med., March 29, 2007; 356(13): 1295 - 1303. [Abstract] [Full Text] [PDF]

				P. J. Wallace Reshaping Cancer Learning Through The Use Of Health Information Technology Health Aff., March 1, 2007; 26(2): w169 - w177. [Abstract] [Full Text] [PDF]

				K. P. Tercyak, B. N. Peshkin, B. M. Brogan, T. DeMarco, M. F. Pennanen, S. C. Willey, C. M. Magnant, S. Rogers, C. Isaacs, and M. D. Schwartz Quality of Life After Contralateral Prophylactic Mastectomy in Newly Diagnosed High-Risk Breast Cancer Patients Who Underwent BRCA1/2 Gene Testing J. Clin. Oncol., January 20, 2007; 25(3): 285 - 291. [Abstract] [Full Text] [PDF]

				A. M. Geiger, C. N. West, L. Nekhlyudov, L. J. Herrinton, I.-L. A. Liu, A. Altschuler, S. J. Rolnick, E. L. Harris, S. M. Greene, J. G. Elmore, et al. Contentment With Quality of Life Among Breast Cancer Survivors With and Without Contralateral Prophylactic Mastectomy J. Clin. Oncol., March 20, 2006; 24(9): 1350 - 1356. [Abstract] [Full Text] [PDF]

				T. M. Vogt and E. H. Wagner Introduction J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 1 - 2. [Full Text] [PDF]

				L. Nekhlyudov, M. Bower, L. J. Herrinton, A. Altschuler, S. M. Greene, S. Rolnick, J. G. Elmore, E. L. Harris, A. Liu, K. M. Emmons, et al. Women's Decision-Making Roles Regarding Contralateral Prophylactic Mastectomy J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 55 - 60. [Abstract] [Full Text] [PDF]

				C. N. West, A. M. Geiger, S. M. Greene, E. L. Harris, I.-L. A. Liu, M. B. Barton, J. G. Elmore, S. Rolnick, L. Nekhlyudov, A. Altschuler, et al. Race and Ethnicity: Comparing Medical Records to Self-Reports J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 72 - 74. [Abstract] [Full Text] [PDF]

				K. J. Helzlsouer Contralateral Prophylactic Mastectomy: Quantifying Benefits and Weighing the Harms J. Clin. Oncol., July 1, 2005; 23(19): 4251 - 4253. [Full Text] [PDF]